Long-Term Treatment With Ocrelizumab in Patients With Early-Stage Relapsing MS

Jahr

2025

Autoren

Cerqueira JJ, Berthele A, Cree BAC, Filippi M, Pardo G, Pearson OR, Traboulsee A, Ziemssen T, Vollmer T, Bernasconi C, Mandel CR, Kulyk I, Chognot C, Raposo C, Schneble HM, Thanei GA, Incera E, Havrdová EK.

Verlag

Neurology. 2025 Feb 25;104(4):e210142.

Link

https://doi.org/10.1212/WNL.0000000000210142

Long-Term Treatment With Ocrelizumab in Patients With Early-Stage Relapsing MS

Ziemssen T, Centonze D. Diagnostic uncertainty in the era of biosimilar natalizumab-The case for harmonizing anti-JCV antibody testing. Mult Scler. 2025 Jun;31(7):751-753. doi: 10.1177/13524585251346658. Epub 2025 Jun 14. PMID: 40515640.

Speech as a digital biomarker in multiple sclerosis: Automatic analysis of speech metrics using a multi-speech-task protocol in a cross-sectional MS cohort study

CONFIDENCE treatment success: long-term real-world effectiveness and safety of ocrelizumab in Germany

RECLAIM—A retrospective, multicenter observational study aimed at enabling the development of artificial intelligence-driven prognostic models for disease progression in multiple sclerosis

Experiences of People with Multiple Sclerosis in Sensor-Based Jump Assessment